Kolexia
Borchiellini Delphine Oncologie médicale
Borchiellini Delphine
Oncologie médicale
Centre Antoine Lacassagne
Nice, France
257 Activités
783 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Carcinomes Néphrocarcinome Tumeurs du rein Tumeurs de la prostate Métastase tumorale Tumeurs prostatiques résistantes à la castration Tumeurs de la vessie urinaire Anémie Carcinome transitionnel

Collaborateurs

Voir plus
Barthelemy Philippe
Barthelemy Philippe
Hôpital Civil, Strasbourg, France
Gravis-Mescam Gwenaelle
Gravis-Mescam Gwenaelle
Centre Paoli-Calmettes, Marseille, France
Pignot Geraldine
Pignot Geraldine
Centre Paoli-Calmettes, Marseille, France
Gross-Goupil Marine
Gross-Goupil Marine
Hôpital Saint-André, Bordeaux, France

Industries

Voir plus
Janssen
53 collaboration(s)
Dernière en 2023
MSD
37 collaboration(s)
Dernière en 2023
Ipsen
35 collaboration(s)
Dernière en 2023
BMS
33 collaboration(s)
Dernière en 2023

Dernières activités

Voir plus
A Study of Lorigerlimab With Docetaxel or Docetaxel Alone in Participants With Metastatic Castration-Resistant Prostate Cancer: A Phase 2, Randomized, Open-Label, Study of Lorigerlimab With Docetaxel or Docetaxel Alone in Participants With Metastatic Castration-Resistant Prostate Cancer
Essai Clinique (MacroGenics)   18 mars 2024
Study to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Axitinib Versus Sunitinib Monotherapy in Participants With Renal Cell Carcinoma (MK-3475-426/KEYNOTE-426): A Phase III Randomized, Open-label Study to Evaluate Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Axitinib Versus Sunitinib Monotherapy as a First-line Treatment for Locally Advanced or Metastatic Renal Cell Carcinoma (mRCC) (KEYNOTE-426)
Essai Clinique (Merck & Co.)   04 mars 2024
Safety and efficacy of nivolumab in elderly patients with metastatic clear cell renal cell carcinoma: Analysis of the NIVOREN GETUG-AFU 26 study.
European journal of cancer (Oxford, England : 1990)   03 février 2024
EDEN: Prospective Therapeutic De-escalation and miRNA-M371 Biomarker Evaluation Phase II Study for Stage IIa/IIb < 3 cm Seminomas
Essai Clinique (Centre Léon-Bérard)   24 janvier 2024
PAXIPEM: Multicenter Phase II Study of Axitinib +/- Pembrolizumab in First Line Treatment for Patients With Locally Advanced or Metastatic Papillary Renal Cell Carcinoma (PRCC)
Essai Clinique (Centre Léon-Bérard)   24 janvier 2024
Corrigendum to "Pembrolizumab Plus Axitinib Versus Sunitinib as First-line Treatment of Advanced Renal Cell Carcinoma: 43-month Follow-up of the Phase 3 KEYNOTE-426 Study" Eur Urol 84(5) (2023) 449-454.
European urology   08 décembre 2023
Néphrectomies « de clôture » post-immunothérapie: facteurs prédictifs de complications peropératoires
117e congrès français d'urologie   01 novembre 2023
EV-103: A Study of Enfortumab Vedotin (ASG-22CE) as Monotherapy or in Combination With Other Anticancer Therapies for the Treatment of Urothelial Cancer
Essai Clinique (Astellas)   17 octobre 2023
Adrenal Metastases Are Associated with Poor Outcomes in Patients with Metastatic Clear Cell Renal Cell Carcinoma Treated with Nivolumab in the GETUG-AFU-26 NIVOREN Phase 2 Trial.
European urology oncology   07 octobre 2023
2364MO Durvalumab (D) +/- tremelimumab (T) in combination with dose-dense MVAC (ddMVAC) as neoadjuvant treatment in patients with muscle-invasive bladder carcinoma (MIBC): Results of NEMIO, a randomized phase I-II trial
Abstract Book of the ESMO Congress 2023, 20 - 24 October 2023.   01 octobre 2023